Tassos Nicolaou

Delpor is a clinical stage biopharmaceuticals company that develops once-yearly therapies for chronic conditions. The technology makes it possible for patients to achieve complete medication adherence for one full year without having to worry about taking their meds. Patients may go through a year without any symptoms, relapses, the stigma of taking medication, or the daily reminder that they are sick, almost like having a one-year cure in a disease area where there is no cure. The company is focusing on CNS indications pursuing 6-12 month formulations of drugs targeting Mental Disorders, Addiction, Neuromuscular Diseases, Neurodegenerative Diseases, and other conditions. Delpor’s lead product is a 1-Year Risperidone for schizophrenia maintenance which is currently in clinical development.

AlphaDetail was a rapidly growing online market research company focused on the biopharmaceutical industry. The company grew from an idea to an established company with over 50,000 physician members and a long list of blue chip pharmaceutical and biotech clients. AlphaDetail was acquired by ImpactRx (part of the Symphony Technology Group) and it is now part of IQVIA.

Negotiated and executed strategic partnerships for Everdream Corporation, a company providing on-demand personal computer and desktop management software services. Everdream was acquired by Dell

Assisted Fortune 500 companies in strategy development and selection in a variety of industries including life sciences, oil & gas, and entertainment. Former clients include Pfizer, Serono (now Merck Serono), Searle (now Pfizer), Chevron, Shell, Sony Pictures, and others. Supported senior executives in pipeline portfolio evaluation, marketing optimization, partner negotiations, as well as other key strategic and operational activities. Structured and delivered strategy seminars to senior executives worldwide, and led SDG’s client education practice for 2 years.